Finanzen von MIRA Pharmaceuticals Inc (MIRA)MIRAMIRA Pharmaceuticals Inc

Evaluating the bottom line, MIRA Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -710.85%, provide a clear picture of how effectively MIRA converts its operational activities into shareholder value.

In the context of the broader market, MIRA competes directly with industry leaders such as MTEX and SCLX. With a market capitalization of $23.97M, it holds a leading position in the sector. When comparing efficiency, MIRA's gross margin of N/A stands against MTEX's 76.87% and SCLX's 24.51%. Such benchmarking helps identify whether MIRA Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Mira Pharmaceuticals has shown a significant decline in share price, with a year-to-date change of -61.71%. Despite this, the company has a strong current ratio of 200.08, indicating good short-term financial health. However, the negative earnings per share (EPS) of -0.03 and a forward P/E of 0 suggest ongoing challenges in profitability.